Effect of the serotonin antagonists ritanserin and ketanserin in Cushing's disease

Pituitary

Volumn 3, Issue 2, 2000, Pages 55-59

  Sonino, N ^a   Fava, G A ^a   Fallo, F ^a   Franceschetto, A ^a   Belluardo, P ^a   Boscaro, M ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Cushing's disease; Ketanserin; Ritanserin; Serotonin

Indexed keywords

CORTICOTROPIN; HYDROCORTISONE; KETANSERIN; RITANSERIN; SEROTONIN 2 ANTAGONIST;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOTROPIN BLOOD LEVEL; CUSHING DISEASE; DRUG EFFECT; DRUG RESPONSE; DRUG WITHDRAWAL; FATIGUE; FEMALE; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYDROCORTISONE URINE LEVEL; LONG TERM CARE; NELSON SYNDROME; PRIORITY JOURNAL; SEROTONINERGIC SYSTEM; SHORT COURSE THERAPY; SOMNOLENCE;

ADOLESCENT; ADRENOCORTICOTROPIC HORMONE; ADULT; CUSHING SYNDROME; FEMALE; HORMONES; HUMANS; HYDROCORTISONE; KETANSERIN; LONG-TERM CARE; MALE; MIDDLE AGED; NELSON SYNDROME; RITANSERIN; SEROTONIN ANTAGONISTS;

EID: 0034432713     PISSN: 1386341X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1009986822146     Document Type: Article

References (39)

1. Cyproheptadine-induced remission of Cushing's disease
2. The medical treatment of Cushing's syndrome
3. Medical therapy for Cushing's disease
4. International union pharmacology classification of receptors for 5-hydroxytryptamine (serotonin)
5. What is the cause of Cushing's disease?
6. Pathogenesis of pituitary Cushing's syndrome
7. Receptor-binding properties in vitro and in vivo of ritanserin
8. 2-antagonist
9. 2C receptor interactions
10. 2 receptor antagonists. Potential in the treatment of psychiatric disorders
11. Impaired growth hormone response to insulin-induced hypoglycemia in obese patients: Restoration blocked by ritanserin after fenfluramine administration
12. 2 antagonist, on PRL secretion in normal subjects and in different hyperprolactinaemic conditions
13. 2 receptor antagonist, does not prevent 5-hydroxytryptophan-induced β-EP, β-LPH and cortisol secretion
14. 2 receptor antagonist, on the release of anterior pituitary hormones during insulin-induced hypoglycemia in normal humans
15. Effects of ritanserin on the behavioral, neuroendocrine, and cardiovascular responses to metachlorophenylpiperazine in healthy human subjects
16. Serotonin and serotonin antagonism in cardiovascular and non-cardiovascular disease
17. Lack of a difference between ketanserin and ritanserin in central versus peripheral serotonin receptor antagonism
18. Comparative pharmacological profile of ritanserin and ketanserin
19. 2 receptor antagonism
20. The effects of ketanserin, a specific serotonin antagonist on the PRL, GH, ACTH and cortisol responses to hypoglycemia in normal subjects
21. Potential therapeutic effects of ritanserin in Cushing's disease
22. The Cushing's syndrome: An update on diagnostic tests
23. Risk factors and long-term outcome in pituitary-dependent Cushing's disease
24. Selective venous sampling in differential diagnosis of ACTH-dependent Cushing's syndrome
25. On a nonparametric combination method for dependent permutation tests with applications
26. Serotonin and dopamine receptors in the rat pituitary gland
27. Evidence that ACTH secretion is regulated by serotonin receptors
28. Serotonin receptors involved in regulation of pituitary-adrenocortical function in rats
29. Serotonin and the regulation of hypothalamic-pituitary-adrenal axis function
30. Mechanisms of serotonin receptor-agonist-induced activation of the hypothalamic-pituitary-adrenal axis in the rat
31. Serotonergic regulation of adrenocortical function
32. A role for life events in the pathogenesis of Cushing's disease
33. Psychosomatic aspects of Cushing's disease
34. Serotonin-induced changes in membrane potential and cytosolic free calcium in a clonal pituitary cell life (AT-20) of cultured mouse corticotropes
35. Faulty cortisol/serotonin interplay
36. Role of 5HT in stress, anxiety, and depression
37. Ketoconazole treatment in Cushing's syndrome: Experience in 34 patients
38. Evidence for two subtypes of Cushing's disease based on the analysis of episodic cortisol secretion
39. Cortisol secretory patterns in Cushing's disease and response to cyproheptadine treatment